To address this, several systematic literature reviews (SLRs) and network meta-analyses (NMAs) were conducted to assess the efficacy and/or safety of TPO-RAs as second-line treatments in patients with ITP [12,13,14,15,16,17,18,19]. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.